Affordable Access

Publisher Website

HER2-Positive Circulating Tumor Cells in Breast Cancer

Authors
Journal
PLoS ONE
1932-6203
Publisher
Public Library of Science
Publication Date
Volume
6
Issue
1
Identifiers
DOI: 10.1371/journal.pone.0015624
Keywords
  • Research Article
  • Biology
  • Biochemistry
  • Cytochemistry
  • Molecular Cell Biology
  • Cytometry
  • Medicine
  • Clinical Immunology
  • Immunologic Techniques
  • Immunofluorescence
  • Diagnostic Medicine
  • Pathology
  • General Pathology
  • Biomarkers
  • Obstetrics And Gynecology
  • Breast Cancer
  • Oncology
  • Cancer Detection And Diagnosis
  • Early Detection
  • Cancers And Neoplasms
  • Breast Tumors
Disciplines
  • Medicine

Abstract

Purpose Circulating Tumor Cells (CTCs) detection and phenotyping are currently evaluated in Breast Cancer (BC). Tumor cell dissemination has been suggested to occur early in BC progression. To interrogate dissemination in BC, we studied CTCs and HER2 expression on CTCs across the spectrum of BC staging. Methods Spiking experiments with 6 BC cell lines were performed and blood samples from healthy women and women with BC were analyzed for HER2-positive CTCs using the CellSearch®. Results Based on BC cell lines experiments, HER2-positive CTCs were defined as CTCs with HER2 immunofluoresence intensity that was at least 2.5 times higher than the background. No HER2-positive CTC was detected in 42 women without BC (95% confidence interval (CI) 0–8.4%) whereas 4.1% (95%CI 1.4–11.4%) of 73 patients with ductal/lobular carcinoma in situ (DCIS/LCIS) had 1 HER2-positive CTC/22.5 mL, 7.9%, (95%CI 4.1–14.9%) of 101 women with non metastatic (M0) BC had ≥1 HER2-positive CTC/22.5 mL (median 1 cell, range 1–3 cells) and 35.9% (95%CI 22.7–51.9%) of 39 patients with metastatic BC had ≥1 HER2-positive CTC/7.5 mL (median 1.5 cells, range 1–42 cells). In CTC-positive women with DCIS/LCIS or M0 BC, HER2-positive CTCs were more commonly detected in HER2-positive (5 of 5 women) than HER2-negative BC (5 of 12 women) (p = 0.03). Conclusion HER2-positive CTCs were detected in DCIS/LCIS or M0 BC irrespective of the primary tumor HER2 status. Nevertheless, their presence was more common in women with HER2-positive disease. Monitoring of HER2 expression on CTCs might be useful in trials with anti-HER2 therapies.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Prognostic value of HER2-positive circulating tumo...

on International journal of clini... April 2012

HER2-positive circulating tumor cells indicate poo...

on Clinical Cancer Research Mar 15, 2006
More articles like this..